PHILADELPHIA — Patients with juvenile idiopathic arthritis started on conventional synthetic and biologic disease-modifying antirheumatic drug therapy concurrently had better results than patients on other plans, according to data presented here.
We’re sorry, but an unexpected error has occurred.
Please refresh your browser and try again. If this error persists, please contact ITSupport@wyanokegroup.com for assistance.
Would you like to receive email reminders to complete your saved activities from Healio CME?
Activity saved! You'll receive reminders to complete your saved activities from Healio CME.